OS. MOZARTA 1/29 31-232 KRAKÓW
(+48) 607 345 792

Publikacje pełnotekstowe

Publikacje pelnotekstowe

  • Holko P, Kawalec P, Pilc A. Impact of Biologic Treatment of Crohn’s Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland. Front Pharmacol. 2018 Jun 11;9:621. doi: 10.3389/fphar.2018.00621.
  • Kawalec P, Malinowski KP, Trąbka W. Trends and determinants in reimbursement decision-making in Poland in the years 2013-2015. Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):197-205. doi: 10.1080/14737167.2018.1384696.
  • Maria Kamusheva,   Manoela Manova,   Alexandra T. Savova,   Guenka I. Petrova, Konstantin Mitov, András Harsányi,   Zoltan Kalo, Kristóf Márky, Pawel Kawalec, Bistra Angelovska at al. Comparative analysis of legislative requirements about patients’ access to biotechnological drugs for rare diseases in Central and Eastern European Countries. Frontiers in Pharmacology 2018. doi: 10.3389/fphar.2018.00795.
  • Holko P, Kawalec P, Pilc A. Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist. Pharmacoeconomics. 2018 Jul;36(7):853-865. doi: 10.1007/s40273-018-0653-2.
  • Kawalec P, Tesar T, Vostalova L, Draganic P, Manova M et al. Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review. Front Pharmacol. 2017 Dec 18;8:892. doi: 10.3389/fphar.2017.00892.
  • Kawalec P, Śladowska K, Malinowska-Lipień I, Brzostek T, Kózka M. European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib. Ther Clin Risk Manag. 2017 Dec 21;14:15-29. doi: 10.2147/TCRM.S138677.
  • Kawalec P, Stawowczyk E, Tesar T, Skoupa J et al. Pricing and Reimbursement of biosimilars in Central and Eastern European Countries. Front Pharmacol. 2017 Jun 8;8:288. doi: 10.3389/fphar.2017.00288.
  • Jahnz-Różyk K, Kawalec P, Malinowski K, Czok K. Drug Policy in Poland. Value Health Reg Issues. 2017 Sep;13:23-26. doi: 10.1016/j.vhri.2017.07.001
  • Kawalec P, Holko P, Moćko P, Pilc A. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Rheumatol Int. 2018 Feb;38(2):189-201. doi: 10.1007/s00296-017-3919-7
  • Stawowczyk E, Kawalec P. A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis. Pharmacoeconomics. 2018 Apr;36(4):419-434. doi: 10.1007/s40273-017-0601-6.
  • Holko P, Kawalec P, Stawowczyk E. Prevalence and drug treatment practices of inflammatory bowel diseases in Poland in the years 2012-2014: an analysis of nationwide databases. Eur J Gastroenterol Hepatol. 2018 Apr;30(4):456-464. doi: 10.1097/MEG.0000000000001047.
  • Holko P, Kawalec P, Mossakowska M. Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study. Eur J Gastroenterol Hepatol. 2018 Feb;30(2):174-180. doi: 10.1097/MEG.0000000000001031.
  • Kawalec P, Moćko P. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn’s disease patients. J Comp Eff Res. 2018 Feb;7(2):101-111. doi: 10.2217/cer-2017-0041.
  • Kawalec P, Holko P, Moćko P, Pilc A. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Rheumatol Int. 2017 DOI:10.1007/s00296-017-3919-7.
  • Holko P, Kawalec P, Stawowczyk E. Epidemiology and drug treatment practices of inflammatory bowel diseases in Poland in the years 2012-2014 – an analysis of nationwide databases. European Journal of Gastroenterology and Hepatology 2017 DOI: 10.1097/MEG.0000000000001047.
  • Kawalec P, Śladowska K, Malinowska – Lipień I, Brzostek T, Kózka M. European perspective on the management of rheumatoid arthritis – clinical utility of tofacitinib. Therapeutics and Clinical Risk Management 2018; 14: 15-29.
  • Kawalec P, Moćko P. Malinowska-Lipień I, Brzostek T. Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn’s disease patients: a systematic review and meta-analysis. Journal of Comparative Effectiveness Research. 2017 DOI: 10.2217/cer-2017-0022.
  • Stawowczyk E, Kawalec P, Pilc A. Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland. Eur. J. Clin. Pharmacol. 2016; 72(11): 1319-25.
  • Kawalec P, Moćko P. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF failure Crohn disease patients. J Comp Eff Res. 2017 Nov 8. DOI: 10.2217/cer-2017-0041.
  • Holko P, Kawalec P, Mossakowska M. Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study. European Journal of Gastroenterology and Hepatology 2017; DOI: 10.1097/MEG.0000000000001031.
  • Moćko P, Kawalec P, Pilc A. Safety profile of biologic drugs in the therapy of inflammatory bowel diseases: a systematic review and network meta-analysis of randomized controlled trials. Clin. Drug Invest. 2017; 37(1): 25-37.
  • Kawalec P, Pilc A. An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis. Arch Med Sci 2016; 12(5): 1097-1109.
  • Malinowski KP, Kawalec P. Health utility of patients with Crohn’s disease and ulcerative colitis: a systematic review and meta-analysis. Expert Rev. Pharmacoecon. Outcomes Res. 2016; 16(4): 441-53.
  • Kawalec P. Indirect costs of inflammatory bowel diseases: Crohn’s disease and ulcerative colitis. A systematic review. Arch Med Sci. 2016; 12(2): 295-302.
  • Kawalec P, Malinowski KP, Pilc A. Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland. Rheumatol Int. 2016; 36(9): 1223-30.
  • Holko P, Kawalec P, Mossakowska M, Pilc A. Health-related quality of life impairment and indirect cost of Crohn’s disease: A self-report study in Poland. PLoS One 2016; 11(12): e0168586.
  • Kawalec P, Malinowska-Lipień I, Brzostek T, Kózka M. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib. Expert Rev. Anticancer Ther. 2016; 16(12): 1303-9.
  • Stawowczyk E, Kawalec P, Pilc A. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland. Pharmacotherapy. 2016; 36(5): 472-81
  • Kryst J, Kawalec P, Pilc A. Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One. 2015; 10(5): e0124279.
  • Malinowski K, Kawalec P, Moćko P. Indirect costs of absenteeism due to rheumatoid arthritis, psoriasis, multiple sclerosis, insulin-dependent diabetes mellitus, and ulcerative colitis in 2012: a study based on real-life data from the Social Insurance Institution in Poland. Expert Rev. Pharmacoecon. Outcomes Res. 2016; 16(2): 295-303.
  • Kawalec P, Moćko P, Pilc A, Radziwon-Zalewska M, Malinowska-Lipień I. Vedolizumab compared with certolizumab in the therapy of Crohn’s disease: a systematic review and indirect comparison. Pharmacotherapy 2016; 36(8): 861-9.
  • Moćko P, Kawalec P, Smela-Lipińska B, Pilc A. Effectiveness and safety of vedolizumab for treatment of Crohn’s disease: a systematic review and meta-analysis. Arch. Med. Sci. 2016; 12(5): 1088-96.
  • Kawalec P, Malinowski K. Indirect health costs in ulcerative colitis and Crohn’s disease: a systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(2): 253-66.
  • Kawalec P, Malinowski K. The indirect costs of systemic autoimmune diseases, systemic lupus erythematosus, systemic sclerosis and sarcoidosis: a summary of 2012 real-life data from the Social Insurance Institution in Poland. Expert Rev. Pharmacoecon. Outcomes Res. 2015; 15(4): 667-73.
  • Stawowczyk E, Malinowski K, Kawalec P, Moćko P. The indirect costs of multiple sclerosis: systematic review and meta-analysis. Expert Rev. Pharmacoecon. Outcomes Res. 2015; 15(5): 759-86.
  • Malinowski K, Kawalec P. The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis. Expert Rev Pharmacoecon. Outcomes Res. 2015; 15(2): 285-300.
  • Kawalec P, Malinowski K. The indirect costs of psoriatic arthritis: systematic review and meta-analysis. Expert Rev. Pharmacoecon. Outcomes Res. 2015; 15(1): 125-32.
  • Kawalec P, Holko P, Stawowczyk E, Borowiec Ł, Filipiak KJ. Economic evaluation of single-pill combination of indapamide and amlodipine in the treatment of arterial hypertension in the Polish setting. Kardiol. Pol. 2015; 73(9): 768-80.
  • Kawalec P, Łopuch S, Mikrut A. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis. Clin. Breast Cancer. 2015; 15(2): 90-100.
  • Łopuch S, Kawalec P, Wiśniewska N. Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: a systematic review and meta-analysis. Hematology. 2015; 20(1): 1-10.